FDA Approves Wegovy for Cardiovascular Risk Reduction (2024)
FDA approved Wegovy in March 2024 to cut cardiovascular risk in adults with heart disease and obesity, after SELECT trial showed a 20% MACE reduction.
WEGOVY: Off-Label Uses
15 source-based articles maintained by the HealthRX.com Editorial Team.
15articles
4topic areas covered
May 25, 2026latest review
WEGOVY: Off-Label Uses library
Showing 15 of 15 clinical reviews.
Wegovy for Alcohol Use Disorder: Evidence, Off-Label Status, and Monitoring
Can Wegovy (semaglutide 2.4 mg) treat alcohol use disorder? Review the clinical trial evidence, off-label prescribing rationale, GRADE quality rating, and monitoring requirements for patients and clinicians.
Wegovy for Alcohol Use Disorder: Evidence, Risks, and What Patients Need to Know
Semaglutide 2.4 mg (Wegovy) is being studied off-label for alcohol use disorder. This guide covers the trial data, mechanistic rationale, GRADE-level evidence, real risks, and how to talk to your prescriber.
Wegovy for Alcohol Use Disorder: Off-Label Dosing Protocol, Evidence, and Clinical Guidance
Can semaglutide 2.4 mg (Wegovy) treat alcohol use disorder? Review the preclinical and early clinical evidence, proposed dosing protocols, and what physicians should know before prescribing off-label.
Wegovy for Alcohol Use Disorder: What the Evidence Actually Shows
Semaglutide 2.4 mg (Wegovy) is not FDA-approved for alcohol use disorder, but emerging preclinical and observational data suggest GLP-1 receptor agonists may reduce alcohol intake. Here is what clinicians and patients need to know.
Wegovy for Binge Eating Disorder: Off-Label Dosing Protocol and Evidence
A clinical review of semaglutide 2.4 mg (Wegovy) used off-label for binge eating disorder, including dosing protocols, trial evidence, safety data, and what patients should discuss with their provider.
Wegovy for Binge Eating Disorder: Off-Label Evidence, Risks, and Clinical Tradeoffs
A clinical review of semaglutide 2.4 mg (Wegovy) used off-label for binge eating disorder, including trial data, risk-benefit analysis, and practical prescribing considerations.
Wegovy for Binge Eating Disorder: Off-Label Use, Evidence, and Monitoring
Semaglutide 2.4 mg (Wegovy) is being used off-label for binge eating disorder. Review the clinical evidence, monitoring protocols, and what patients and clinicians should track during treatment.
Wegovy for Binge Eating Disorder: What the Evidence Actually Shows
What research does and does not show about semaglutide for binge-eating disorder, how this differs from obesity treatment, and why diagnosis-specific care matters.
Wegovy for Cardiovascular Prevention: Evidence Summary
A clinical evidence summary of semaglutide 2.4 mg (Wegovy) for cardiovascular prevention, covering SELECT trial data, FDA-approved indications, off-label context, and GRADE-level evidence ratings.
Wegovy for Cardiovascular Prevention: Evidence, Off-Label Status, and Risk-Benefit Tradeoffs
Wegovy (semaglutide 2.4 mg) now has FDA-approved cardiovascular data from SELECT, but using it purely for CV prevention without a weight-loss indication remains off-label. Here is what the evidence actually shows, what guidelines say, and how clinicians should weigh the tradeoffs.
Wegovy for Cardiovascular Prevention: Off-Label Dosing Protocol, Evidence, and Clinical Guidance
Semaglutide 2.4 mg (Wegovy) reduces major cardiovascular events by 20% in the SELECT trial. Learn when CV prevention use is on-label vs. off-label, the dosing protocol, evidence grade, and what clinicians should consider.
Wegovy for NASH: Off-Label Evidence Summary
A clinical evidence review of semaglutide 2.4 mg (Wegovy) for nonalcoholic steatohepatitis (NASH/MASH), covering phase 2 and phase 3 trial data, mechanism of action, GRADE-level assessment, and practical prescribing considerations.
Wegovy for NASH: Off-Label Evidence, Risks, and Clinical Tradeoffs
Semaglutide 2.4 mg (Wegovy) is not FDA-approved for NASH. Here is what the phase 2 trial data shows about NASH resolution, the risks of off-label use, and how clinicians weigh the tradeoffs.
Wegovy for NASH: Off-Label Use, Evidence, and Monitoring
Semaglutide 2.4 mg (Wegovy) is used off-label for NASH/MASH. Learn the clinical trial evidence, monitoring schedule, liver enzyme targets, and what your provider should track.